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Four platinum(II) and 4 platinum(IV) complexes with the structures [PtL2 Cl2 ], [PtL2 I2 ], [PtL2 Cl4],
and [PtL2 Cl2 (OH)2] (L = 5(6)-non/orchloro-substituted-2-hydroxymethylbenzimidazole ligands as “nonleaving groups”), respectively, were synthesized and characterized by their elemental analyses, and IR
and 1 H-NMR spectra. In vitro cytotoxic activities of the platinum(II) and platinum(IV) complexes were
tested against the human MCF-7 (breast cancer) and HeLa (cervix cancer) cell lines using the cell culture
method. In general, the platinum(II) complexes were more active than the corresponding platinum(IV)
complexes. The complexes, which were found to be less active than cisplatin, exhibited cyctotoxicity
comparable to carboplatin on the human MCF-7 and HeLa cell lines.
Key Words: Benzimidazole, cytotoxic activity, HeLa cell line, MCF-7 cell line, platinum(IV) complexes,
platinum(II) complexes.

Introduction
Cisplatin [cis-diamminedichloroplatinum(II)], and other platinum-based drugs, such as carboplatin [cisdiammine(1,1-cyclobutanedicarboxylato)platinum(II)] and oxaliplatin [trans-R, R-cyclohexane-1,2-diamine
∗ Corresponding
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oxalatoplatinum(II)], are used to treat testicular tumors as well as a variety of other human solid tumors,
but many are intrinsically resistant and acquired resistance commonly develops during treatment.1
DNA is the principal cellular target of these compounds.2 The major adducts are 1,2-intrastrand and
1,3-intrastrand cross-links.3
Platinum drug resistance can occur by several mechanisms, including drug eﬄux, drug inactivation,
alterations in drug target, processing of drug-induced damage, decreased drug penetration, and evasion
apoptosis.4
Cells deﬁcient in DNA repair enzymes are hypersensitive to cisplatin, indicating that repair plays an
important role in the molecular mechanism of the drug.5
Nucleotide excision repair is a major cellular defense mechanism against the toxic eﬀects of the
anticancer drug cisplatin and other platinum-based chemotherapeutic agents.6
The need for cisplatin analogs that are less toxic and have a broader spectrum of activity led to the
synthesis of a large number of platinum complexes over the past 3 decades.7
The diﬀerent nature of the DNA adduct formed by some targeted platinum complexes may overcome
resistance based on improved nucleotide excision repair of cisplatin DNA adducts.8
The replacement of the leaving chloride groups aﬀects mainly tissue and intracellular distribution of the
cisplatin analogues. On the other hand, the replacement of ammine groups can result in diﬀerent structural
and conformational alterations in target DNA, which may aﬀect the character of biological eﬀects of the
analogues.4 Using more hydrophobic cisplatin analogues was expected to enhance aﬃnity of the damagerecognition proteins to the platinated site, which could more eﬀectively protect it from excision repair. It
has been shown that increasing cytotoxicity of cisplatin analogues, in which NH3 groups were replaced by
more hydrophobic amine ligands, correlated with growing hydrophobicity of these analogues.9
There is growing interest in 6-coordinated platinum(IV) complexes because of their anticancer activity,
especially since these complexes are toxic to tumors that are resistant to cisplatin.10
Some platinum(IV) complexes have shown potential as powerful anticancer drugs. It is widely thought
that reduction to platinum(II) is essential for the anticancer activity of platinum(IV) complexes to be eﬀected.
The reduction potentials of diam(m)ine platinum(IV) complexes are dependent on the nature of the axial
and equatorial ligands, but the axial ligands generally exert the stronger inﬂuence.11
On the other hand, there are a few papers reporting that platinum(IV) complexes can bind to DNA
and RNA fragments without being reduced.12
Although some platinum(IV) compounds, including iproplatin, [cis-dichloro-trans-dihidroxybis(isopropylamine)platinum(IV)], tetraplatin, [tetrachloro[(1,2-diaminocyclohexane)platinum(IV)]], and satraplatin,
[trans,cis-bis(acetato) amminedichloro(cyclohexylamine)platinum(IV)cyclohexylamine], have been tested in
clinical trials, there are still no platinum(IV)-based therapeutics in routine clinical use.7,11−13
In a previous paper, we reported the synthesis and characterization of the platinum complexes of the
structure cis-[Pt(L2 )Cl2 ].H2 O, where L is 5(6)-non/or chloro-substituted-2-hydroxymethylbenzimidazole,
and the determination of their preliminary in vitro cytotoxic eﬀects by Rec-Assay test.14 The DNA-binding
properties of these 2 platinum(II) complexes were also examined and it was determined that the DNA
platinated with these compounds was speciﬁcally recognized by high mobility group (HMG) domain protein,
HMG 1.15 It was also determined that some of the new 2-substituted benzimidazoleplatinum(II) complexes
we synthesized have in vitro cytotoxic activities on the human RD (Rhabdomyosarcoma),16 MCF-7, and
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HeLa cell lines.17,18
In the present study, as an extension of the investigation on the probable antitumor activity of
platinum complexes of benzimidazole ligands, to determine the eﬀect of axial and equatorial ligand variation
on the cytotoxic activities of the platinum complexes, a series of platinum(II) and platinum(IV) complexes
with 2-hydroxymethylbenzimidazole (L1 ) or 5(6)-chloro-2-hydroxymethylbenzimidazole (L2 ) as non-leaving
amine ligands and chloro, iodo, hydroxo ligands as leaving groups were synthesized and evaluated for their
preliminary in vitro cytotoxic activities on the human MCF-7 and HeLa cell lines.

Experimental
Chemistry
Materials
All chemicals and solvents used in the synthesis were purchased from Merck and Aldrich. The cisplatin and
carboplatin used in the cytotoxicity test were purchased from Sigma.
Melting points were measured on an Electrothermal 9200 melting point apparatus and are uncorrected.
Elemental analyses were performed with a LECO CHNS 932 analyzer at TÜBİTAK Instrumental Analyses
Center (Ankara, Turkey). IR spectra of the compounds were recorded in KBr pellets and in Nujol mulls on
a Bruker Vector 22 IR spectrophotometer.

1

H-NMR spectra were recorded in DMSO-d6 on a Bruker 400

AC NMR spectrometer. Thin-layer chromatography (TLC) was performed on pre-coated aluminum plates
Merck Silica Gel 60 F254 . Plates were visualized by UV light, Dragendorﬀ reagent, or iodine vapor.

Biological test
Preliminary cytotoxicity test
Cell lines and growth conditions
The human MCF-7 and HeLa cell lines used in this study were obtained from the Cell Culture Collection
(HUKUK No: 00092502 and 90061901, respectively) of the Institute for Foot and Mouth Disease (IFMD,
Turkey).
The cells were grown in Dulbecco’s (Seromed, Germany) minimal essential medium (DMEM) enriched
with 10% fetal calf serum (FCS) (Biochrom, Germany), 100 mg mL−1 streptomycin, and 100 IU mL−1
penicillin in a humidiﬁed atmosphere of 5% CO2 at 37 ◦ C. The cells were harvested using Trypsin (Bibco
Life Technologies, UK)/Versen (0.05%:0.02%) solution. Mycoplasma contamination was routinely monitored
and only mycoplasma-free cultures were used.
In vitro chemosensitivity assay on the human MCF-7 and HeLa cancer cell lines
The preliminary in vitro testing of the platinum complexes on antitumor activity was carried out on human
MCF-7 and HeLa cells according to a previously published microtiter test.21 Brieﬂy, the cells were seeded
into 96-well plates (Greiner GmbH, Germany) in a volume of 100 µL so as to be 18-22 cells per microscopic
area. After attachment to the culture surface, the cells were incubated in an atmosphere containing 5%
CO2 at 37 ◦ C for 24 h. After 48 h, the growth medium was carefully removed by suction and 200 µL of
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fresh medium was added to each well. The medium used contained an adequate volume of a stock solution
of the respective compound in order to obtain the desired test concentration (0.5, 1, 5, 10, 20, and 40 µM,
solvent: DMSO, the complexes tested were added to the culture medium such that the ﬁnal DMSO was 0.1%
(v/v)). Sixteen wells were used for each compound (C1-C8, cisplatin, and carboplatin) tested in individual
concentrations, while 16 wells were reserved for the cell culture control, which contained the corresponding
amount of DMSO. After 72 h of incubation at 37 ◦ C, the medium was removed and the cells were ﬁxed with
100 µL of 1% glutardialdehyde in phosphate-buﬀered saline (PBS) per well for 25 min. The ﬁxative was
replaced by 150 µL of PBS per well and the plates were stored in the refrigerator (4 ◦ C). Cell biomass was
determined by a crystal violet stained technique.22
The eﬀects of the platinum complexes were expressed as corrected T/C values according to the
following equation:

T/Ccorr. [%] = [(T – Co )/(C – Co )] × 100

where T is the mean absorbance of the treated cells, C the mean absorbance of the controls, and Co the
mean absorbance of the cells at the time (t = 0) when the drug was added.
When the absorbance of treated cells was less than that of the culture at t = 0 (Co ), the extent of
cell killing was calculated as
Cytocidal eﬀect [%] = [(Co – T)/ Co ] × 100
Absorbance was measured at 578 nm using a Titertek Multiscan plus MKII Autoreader. The results
correspond to 3 independent experiments.

Results and Discussion
Results
Synthesis of the ligands
The ligands, 2-hydroxymethylbenzimidazole (L1 ) and 5(6)-chloro-2-hydroxymethyl benzimidazole (L2 ), were
prepared according to the Phillips method19,20 as shown in the Figure.
2-Hydroxymethylbenzimidazole (L1): Yield 59%.

1

H-NMR (DMSO-d6 ): δ (ppm) 12.17 (s, 1H, N-

H, exchangeable with D2 O), 7.45-7.47 (m, 2H, ArH), 7.07-7.16 (m, 2H, ArH), 5.53 (broad s, 1H, -OH
exchangeable with D2 O), 4.68 (s, 2H,-CH2 -).
5(6)-Chloro-2-hydroxymethylbenzimidazole (L2 ): Yield 34%.

1

H-NMR (DMSO-d6 ): δ (ppm) 12.50

(broad s, 1H, N-H, exchangeable with D2 O), 7.53-7.48 (m, 2H, ArH), 7.17-7.15 (m, 1H, ArH), 5.75 (broad
t, J = 5.2 Hz, 1H, -OH exchangeable with D2 O), 4.69 (d, J = 4.8 Hz, 2H, -CH2 -).
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Figure. Synthesis of the carrier ligands, and platinum(II) and platinum(IV) complexes.

Synthesis of the platinum(II) complexes
Complexes cis-[dichloro-di(2-hydroxymethylbenzimidazole)platinum(II)] (C1) and cis-[dichloro-di(5(6)-chloro2-hydroxymethylbenzimidazole)platinum(II)] (C2) were synthesized as described previously14 by the reac507
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tion of L1 or L2 and K2 PtCl4 in ethanol/water solution as presented in the Figure.
cis-[Dichloro-di(2-hydroxymethylbenzimidazole)platinum(II)].3H2O [PtL12 Cl2 ].3H2 O
(C1)
Yield 25%. 1 H-NMR (DMSO-d6 ): δ (ppm) 13.41 (s, 2H, 2x N-H, exchangeable with D2 O), 8.14 (d,
J= 8.97 Hz, 2H, ArH), 7.57-7.37 (m, 6H, ArH), 6.28 (s, 2H, 2x O-H, exchangeable with D2 O), 5.48 (dd, J
= 4.0 and 16.4 Hz, 2H, -CH2 -), 5.07-4.92 (m, 2H, -CH2 -). IR (KBr): υ 330, 318 (Pt-Cl) cm−1 . Anal. Calcd.
for C16 H16 Cl2 N4 O2 Pt.3H2 O: C, 31.18; H, 3.60; N, 9.09. Found: C, 31.12; H, 3.42; N, 9.30.
cis-[Dichloro-di(5(6)-chloro-2-hydroxymethylbenzimidazole)platinum(II)] [PtL22 Cl2 ] (C2)
Yield 42%.

1

H-NMR (DMSO-d6 ): δ (ppm) 13.29 (broad s, 2H, 2x N-H, exchangeable with D2 O),

8.16-7.79 (m, 2H, ArH), 7.36-7.17 (m, 4H, ArH), 6.12 (broad s, 2H, 2x O-H, exchangeable with D2 O), 5.424.69 (m, 4H, 2x -CH2 -). IR (KBr): υ 330 and 310 (Pt-Cl) cm−1 . Anal. Calcd. for C16 H14 Cl4 N4 O2 Pt: C,
30.44; H, 2.23; N, 8.87. Found: C, 30.09; H, 2.07; N, 8.80.
cis-[Diiodo-di(2-hydroxymethylbenzimidazole)platinum(II)] [PtL12 I2 ] (C3)
K2 PtCl4 (0.422 g, 1.02 mmol) and KI (0.678 g, 4.08 mmol) were dissolved in water (15 mL) and
stirred at 60 ◦ C for 45 min. Then L1 (0.300 g, 2.03 mmol) in a 2/8 ethanol/water mixture (10 mL) was
added dropwise to the resulting K2 PtI4 . The reaction mixture, protected from light, was heated at 60 ◦ C
for 2 days. The resulting yellowish precipitate was ﬁltered oﬀ, washed several times with small portions of
water, ethanol, and diethylether, and dried in vacuo. Yield 36%. 1 H-NMR (DMSO-d6 ): δ (ppm) 13.18 (s,
2H, 2x N-H, exchangeable with D2 O), 8.13-8.00 (m, 2H, ArH), 7.36-7.12 (m, 6H, ArH), 6.18 (t, J = 5.4 Hz,
1H, O-H, exchangeable with D2 O), 6.10 (t, J = 5.6 Hz, 1H, O-H, exchangeable with D2 O), 5.27-5.21 (m,
2H, -CH2 -), 5.00 (dd, J =5.3 Hz, and 16.00 Hz, 1H, -CH2 -), 4.54 (dd, J =5.7 Hz, and 16.00 Hz, 1H, -CH2 -).
Anal. Calcd. for C16 H16 I2 N4 O2 Pt: C, 25.79; H, 2.16; N, 7.52. Found: C, 26.19; H, 2.03; N, 7.38.
cis-[Diiodo-di(5(6)-chloro-2-hydroxymethylbenzimidazole)platinum(II)].0.5 CH3 CH2 OH,
[PtL22 I2 ].0.5

CH3 CH2 OH (C4)

A procedure similar to that described for C3 was carried out using L2 (0.370 g, 2.03 mmol) and
K2 PtCl4 (1.000 g, 2.40 mmol) at 60 ◦ C for 3 days. Yield 60%. 1 H-NMR (DMSO-d6 ): (δ ppm) 13.47 (t, J
=32.3 Hz, 2H, 2x N-H, exchangeable with D2 O), 8.28-8.11 (m, 2H, ArH), 7.53-7.29 (m, 4H, ArH), 6.30-6.15
(m, 2.5H, 2x O-H and 0.5 CH3 CH2 OH exchangeable with D2 O), 5.27–5.34 (m, 2H, -CH2 -), 4.97–5.08 (m, 1H,
-CH2 -), 4.47–4.51 (m, 1H, -CH2 -), 3.45 (q, J = 1.7 Hz, 1H, 0.5 CH3 CH 2 OH), 1.06 (t, J =7.0 Hz, 1.5H, 0.5
CH 3 CH2 OH). Anal. Calcd. for C16 H14 Cl2 I2 N4 O2 Pt. 0.5 CH3 CH2 OH: C, 24.39; H, 2.04; N, 6.69. Found:
C, 24.86; H, 2.14; N, 6.52.
Synthesis of the platinum(IV) complexes
cis, trans, cis-[Dichloro-dihydroxy-di(2-hydroxymethylbenzimidazole)platinum (IV)] [PtL12 Cl2
(OH)2 ] (C5)
To a suspension of C1 (0.140 g, 0.23 mmol) in water (15 mL) was added an aqueous solution of 30%
of H2 O2 (1 mL), and the solution was stirred at 60 ◦ C for 5 days. The resulting pale yellow precipitate
was ﬁltered oﬀ, washed several times with small portions of water, ethanol, acetone, and diethylether, and
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dried in vacuo. Yield 46%. 1 H-NMR (DMSO-d6 ): δ (ppm) 13.50 (s, 2H, 2x N-H, exchangeable with D2 O),
8.03-7.96 (m, 2H, ArH), 7.49-7.23 (m, 6H, ArH), 6.22 (broad s, 2H, 2x –OH, exchangeable with D2 O), 5.36
(d, J =47.2 Hz, 2H, -CH2 -), 4.83 (dd, J =20.0 and 47.2 Hz, 2H, -CH2 -), 2.89 (s, 1H, Pt-OH, exchangeable
with D2 O), 2.74 (s, 1H, Pt-OH, exchangeable with D2 O). IR (KBr): υ 540 (Pt-O) and 340 (Pt-Cl) cm−1 .
Anal. Calcd. for C16 H18 Cl2 N4 O4 Pt: C, 32.22; H, 3.04; N, 9.39. Found: C, 32.03; H, 3.40; N, 8.99.
cis, trans, cis-[Dichloro-dihydroxy-di(5(6)-chloro-2-hydroxymethylbenzimidazole) platinum(IV)].0.5 CH3 COCH3 , [PtL22 Cl2 (OH)2 ].0.5 CH3 COCH3 (C6)
A procedure similar to that described for C5 was carried out using C2 (0.150 g, 0.23 mmol) at 60
◦

C for 5 days. Yield 46%. 1 H-NMR (DMSO-d6 ): δ (ppm) 13.27 (broad s, 2H, 2x N-H, exchangeable with

D2 O), 8.40-6.90 (m, 6H, ArH), 6.12 (broad s, 2H, 2x O-H, exchangeable with D2 O), 5.40-4.45 (m, 4H, 2x
-CH2 -), 2.80 (s, 1H, Pt-OH, exchangeable with D2 O), 2.64 (s, 1H, Pt-OH, exchangeable with D2 O), 1.80
(s, 3H, 0.5 CH3 COCH3 ). IR (KBr): υ 1654 (C=O), 545 (Pt-O) and 335 (Pt-Cl) cm−1 . Anal. Calcd. for
C16 H16 Cl4 N4 O4 Pt.0.5 CH3 COCH3 : C, 30.28; H, 2.76; N, 8.07 Found: C, 30.60; H, 2.85; N, 8.52.
cis-[Tetrachloro-di(2-hydroxymethylbenzimidazole)platinum(IV)] [PtL12 Cl4 ] (C7)
C5 (0.060 g, 0.10 mmol) was dissolved in aqueous 2 M HCl (5 mL) and heated at 60 ◦ C for 1 day. The
resulting precipitate was ﬁltered oﬀ, washed several times with small portions of water, ethanol, acetone,
and diethylether, and dried in vacuo. Yield 23%.

1

H-NMR (DMSO-d6 ): δ (ppm) 13.73 (broad s, 2H, 2x

N-H, exchangeable with D2 O), 8.04-7.16 (m, 8H, ArH), 6.13 (broad s, 2H, 2x O-H, exchangeable with D2 O),
5.49-4.38 (m, 4H, 2x -CH2 -). IR (KBr): υ 340 (Pt-Cl) cm−1 . Anal. Calcd. for C16 H16 Cl4 N4 O2 Pt: C, 30.34;
H, 2.54; N, 8.84 Found: C, 29.90; H, 2.90; N, 8.93.
cis-[Tetrachloro-di(5(6)-chloro-2-hydroxymethylbenzimidazole)platinum(IV)] .CH3
COCH3 , [PtL22 Cl4 ].CH3 COCH3 (C8)
A procedure similar to that described for C7 was carried out using C6 (0.150 g, 0.23 mmol) at 60 ◦ C
for 1 day. Yield 64%. 1 H-NMR (DMSO-d6 ): δ (ppm) 13.70 (broad s, 2H, 2x N-H, exchangeable with D2 O),
8.10-7.01 (m, 6H, ArH), 6.61 (s, 1H, -OH, exchangeable with D2 O), 6.56 (s, 1H, -OH, exchangeable with
D2 O), 5.40-4.38 (m, 4H, 2x -CH2 -), 1.77 (s, 6H, CH3 COCH3 ). IR (KBr): υ 1697 (C=O) and 342 (Pt-Cl)
cm−1 . Anal. Calcd. for C16 H14 Cl6 N4 O2 Pt.CH3 COCH3 : C, 30.02; H, 2.65; N, 7.37 Found: C, 30.53; H,
2.53; N, 7.94.
Preliminary cytotoxicity test
The preliminary antiproliferative activities of the platinum(II) complexes bearing L1 or L2 as “non-leaving
ligands” and chloro or iodo atoms as “leaving ligands”, and the platinum(IV) complexes, which were
the oxidation products of the platinum(II) complexes, C5-C8, with axial chloro or hydroxo ligands were
determined on the human MCF-7 and HeLa cell lines. MCF-7 and HeLa cells were incubated for 72 h
with 40, 20, 10, 5, 1, 0.5 µM of the platinum(II) and platinum(IV) complexes and cisplatin and carboplatin
were used as reference compounds. The antiproliferative activity values of the complexes and the reference
compounds expressed as T/Ccorr. are presented in Tables 1 and 2.
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Table 1. Cytotoxic activities of the platinum(II) and platinum(IV) complexes on the MCF-7 cell line.

Compound
40 µM
C1
12.11 ± 7.07
C2
5.31 ± 1.46
C3
-25.00 ± 9.01b
C4
-27.01 ± 10.71b
C5
32.78 ± 7.25
C6
36.97 ± 5.93
C7
27.34 ± 4.55
C8
20.64 ± 4.04
Cisplatin
-49.23 ± 6.25b
Carboplatin
-9.95 ± 9.25b
a
S.D. Standard deviation.
b
Cytocidal eﬀect.

[T/C]corr. (%) (S.D.)a
20 µM
10 µM
44.56 ± 5.66
68.15 ± 1.41
44.58 ± 0.93
76.11 ± 0.36
8.39 ± 11.87
30.39 ± 4.70
19.52 ± 1.74
49.29 ± 2.93
22.33 ± 4.72
62.89 ± 13.19
84.26 ± 4.38
94.55 ± 2.46
70.30 ± 2.08
84.13 ± 4.76
66.27 ± 3.08
80.63 ± 8.85
-42.60 ± 9.23b -22.30 ± 3.00b
-9.10 ± 3.51b
87.22 ± 20.17

5 µM
83.50 ± 6.36
92.21 ± 4.70
59.69 ± 10.84
73.64 ± 11.61
81.41 ± 1.22
> 100
> 100
> 100
10.22 ± 5.12
81.54 ± 1.32

1 µM
> 100
> 100
> 100
> 100
> 100
> 100
> 100
> 100
66.70 ± 9.10
> 100

0.5 µM
> 100
> 100
> 100
> 100
> 100
> 100
> 100
> 100
82.50 ± 4.9
> 100

Table 2. Cytotoxic activities of the platinum(II) and platinum(IV) complexes on the HeLa cell line.

Compound
40 µM
C1
6.67 ± 3.55
C2
24.72 ± 3.39
C3
-40.31 ± 13.47b
C4
-30.24 ± 7.09b
C5
34.73 ± 2.73
C6
72.55 ± 5.78
C7
55.29 ± 1.67
C8
67.28 ± 3.23
Cisplatin
-53.12 ± 1.59b
Carboplatin
16.67 ± 9.87
a
S.D. Standard deviation.
b
Cytocidal eﬀect.

[T/C]corr. (%) (S.D.)a
20 µM
10 µM
5 µM
32.25 ± 5.65
67.63 ± 10.61
93.85 ± 2.13
54.25 ± 2.82
88.13 ± 4.24
> 100
37.65 ± 4.53
61.70 ± 1.19
74.24 ± 1.47
62.77 ± 3.53
86.45 ± 2.54
> 100
64.74 ± 3.65
74.34 ± 5.68
> 100
96.56 ± 5.58
> 100
> 100
82.93 ± 17.61
85.84 ± 1.78
> 100
80.90 ± 11.91
90.34 ± 7.14
90.54 ± 13.70
-55.26 ± 4.46b -54.22 ± 4.25b -53.18 ± 1.48b
56.75 ± 14.78
69.91 ± 12.28
85.23 ± 4.14

1 µM
> 100
> 100
> 100
> 100
> 100
> 100
> 100
> 100
12.50 ± 1.8
> 100

0.5 µM
> 100
> 100
> 100
> 100
> 100
> 100
> 100
> 100
48.2 ± 8.34
> 100

Discussion
Synthesis and characterization of the complexes
The ligands L1 and L2 , used as “non-leaving ligands” in the structure of the platinum(II) and platinum(IV)
complexes, were prepared according to the Phillips method as shown in the Figure. The ligands had been
reported previously and their melting points and IR and 1 H-NMR spectral data were in accordance with
the literature.14
The procedures of the synthesis of platinum(II) and platinum(IV) complexes are shown in the Figure.
Platinum(II) complexes of the type [Pt(L1 or L2 )2 Cl2 ] (C1 or C2) were synthesized as described previously
by the reaction of the corresponding ligands and K2 PtCl4 in ethanol/water solution. IR and 1 H-NMR
spectral data of the complexes C1 and C2 were in accordance with the data reported previously.14
Reaction of K2 PtCl4 with an excess of KI produced K2 PtI4 in solution. K2 PtI4 was then reacted with
2 equivalents of L1 or L2 to obtain platinum(II) complexes of the type [Pt(L1 or L2 )2 I2 ] (C3 or C4).
The dichloro complexes [Pt(L1 or L2 )2 Cl2 ] were used as the precursor for platinum(IV) complexes
C5-C8.
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Platinum(II) complexes of the type [Pt(L1 or L2 )2 Cl2 ] were oxidized with 30% H2 O2 to form corresponding axial dihydroxyplatinum(IV) complexes C5 and C6. Complexes C7 and C8 were obtained by the
reaction of the dihydroxyplatinum(IV) complexes with 2 M HCl.
The chemical structures of the platinum(II) and platinum(IV) complexes were characterized by their
elemental analyses and 1 H-NMR and IR spectra compared with those of the ligands. The elemental analyses
and spectroscopic data conﬁrm the structure of the complexes.
For complexes C1, C4, C6, and C8 molecules of water, ethanol, acetone, and acetone, respectively,
were included as justiﬁed by the analytical results. With the exception of water molecules (for C1) these
were also observed clearly in the 1 H-NMR spectra of the complexes. It is expected that C2, C4, C6, and
C8 bearing ligand L2 are probably a mixture of constitutional isomers since more than one isomer could be
formed from L2 upon coordination to platinum. Similar IR and 1 H-NMR spectral data have been reported
in our previous papers for platinum(II) complexes of diﬀerently substituted benzimidazoles. Most of the
general points have been discussed in the previous papers.14,16−18,23
In their IR spectra the ligands L1 and L2 show very broad bands in the region 3500-2300 cm−1 due to
the inter-molecular hydrogen bonded imidazole N-H. The platinum(II) complexes exhibited N-H stretching
bands centered at 3230 cm−1 sharper than those of the free ligands due to breaking of tautomerism.24,25
In the IR spectra of the platinum(IV) complexes C5-C8, N-H stretching vibrations appeared at highest
frequencies from 3443 to 3650 cm−1 . Being inﬂuenced by oxidation states of the central metal, the N-H
vibrations in platinum(IV) compounds were broad in comparison with those in platinum(II) compounds.26
The platinum(II) complexes C1 and C2 showed in their IR spectra characteristic Pt-Cl stretching
vibrations in the region 310-330 cm−1 . These bands were shifted (∼10 cm−1 ) towards higher frequencies
in the spectra of platinum(IV) C5-C8 upon oxidation.27 The complexes C5-C8 exhibit only one υ (Pt-Cl)
absorption; this is consistent with the literature.28 (Pt-I) band of the cis-diiodo complexes should show
195-183 cm−1 in the far-IR region of the complexes spectra.29 The υ (Pt-I) stretching bands for C3 and C4
could not be measured on the spectrophotometer used.
The hydroxyplatinum(IV) complexes C5 and C6, which were obtained by the oxidation reactions of
C1 and C2 with hydrogen peroxide, were readily identiﬁed by their characteristic PtO-H stretching bands
at 3480 and 3445 cm−1 and Pt-O stretching bands at 540 and 545 cm−1 , respectively.30,31
The insolubility of the complexes in the other organic solvents made it necessary to record 1 H-NMR
spectra in dimethylsulfoxide-d6 (DMSO-d6 ). All 1 H-NMR measurements were recorded immediately in order
to avoid the ligand exchange reaction between the platinum complexes synthesized and DMSO-d6 . Almost
all signals were shifted upon complexation as the result of the electric ﬁeld eﬀect caused by complexation.
The large downﬁeld shifts in the imidazole N-H signal in the spectra of the complexes with respect
to their ligands are a result of an increase in the N-H acid character after platinum binding.32 That the
4 protons are not chemically equivalent is indicated by the split 1 H-NMR signals corresponding to the 2
methylene groups of the platinum complexes. The splittings are probably due to restricted rotation of the
methylene groups. The 1 H-NMR signals of the platinum complexes tend to broaden, which is consistent
with the literature.33
1

H-NMR spectra of C5 and C6 showed clearly 2 distinguished singlets for -OH ligands.
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Preliminary cytotoxicity test
In the test on the human MCF-7 and HeLa cancer cell lines at 0.5 and 1 µM concentration T/Ccorr. values
of all complexes synthesized and the reference compound carboplatin were >100. At these concentrations
on the HeLa cell line the reference compound cisplatin possessed considerably higher activity.
At a dose of 5 and 10 µM (except for C3 at 10 µM concentration on MCF-7 cell line) no signiﬁcant
cytotoxicity on MCF-7 and HeLa cell lines was observed for any of the complexes synthesized.
On the MCF-7 cell line at 10 µM concentration among the complexes synthesized, platinum(II)
complexes bearing iodo ligands, C3 and C4, were found to be the most active compounds, with T/Ccorr.
values of around 30% and 49%, respectively.
Considerable T/Ccorr. values of all the complexes synthesized on the MCF-7 cell line were at 40 µM
concentration. At this concentration cytocidal eﬀects were obtained for C3 and C4. A clear antiproliferative
eﬀect on the HeLa cell line was observed only for complexes C1-C4 by increasing the concentration to 40
µM.
All complexes tested showed a concentration-dependent reduction in cell proliferation. The test results
show that replacing the chloro ligands with the iodo ligands has signiﬁcant eﬀects on the antiproliferative
activities of the platinum(II) complexes.
The overall potencies of the platinum(IV) complexes were less than those obtained for the platinum(II)
complexes and the reference compounds cisplatin and carboplatin.
It is generally thought that since platinum(IV) complexes are inert on ligand substitution reactions
relative to their platinum(II) analogues they must be reduced to platinum(II) species before binding to
DNA. The reduction potentials of diam(m)ine platinum(IV) complexes are dependant on the nature of the
axial and equatorial ligands, but the axial ligands generally exert the stronger inﬂuence.11 On the other
hand, Choi et al.12 studied a range of complexes and suggested that the rate of reduction of platinum(IV)
complexes depended on the bulkiness of the equatorial ligands. Although more factors are involved for the
cytotoxicity of platinum(IV) complexes, including membrane transport, absorption, reduction, and possibly
direct interaction with DNA, the steric hindrance of the “non-leaving ligands” of the platinum(IV) complexes
(C5-C8) may be related to their lower cytotoxicity than the corresponding platinum(II) complexes.

Conclusion
In general, it was found that the platinum(II) complexes were more active than the platinum(IV) complexes. The complexes, which were found to be less active than cisplatin, exhibited moderate cyctotoxicity
comparable to carboplatin on the MCF-7 and HeLa cell lines.
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